• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

    11/28/23 7:56:49 AM ET
    $ALYA
    $ARGX
    $ASST
    $CWBR
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALYA alert in real time by email

    Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors.

    SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • SaverOne 2014 Ltd (NASDAQ:SVRE) shares rose 74.8% to $0.7389 in pre-market trading. SaverOne announced withdrawal of proposed public offering due to market conditions.
    • ESGL Holdings Limited (NASDAQ:ESGL) shares rose 54.3% to $1.38 in pre-market trading after the company disclosed a multi-year contract renewal with Singapore Refining Company Private Limited.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) rose 27.5% to $0.2735 in pre-market trading. Heart Test Laboratories 13G filing showed Icahn School of Medicine at Mount Sinai ("ISMMS") EIN 13-6171197 reported a 9.9% stake in the company, as of Nov. 16, 2023.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) shares surged 21% to $1.21 in pre-market trading. Redhill Biopharma shares jumped 217% on Monday after the company announced the FDA has granted five years' market exclusivity for Talicia.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) gained 18.2% to $0.2910 in pre-market trading after falling around 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares rose 10.3% to $0.4633 in pre-market trading after falling more than 25% on Monday. TC Biopharm announced FDA clearance of the Phase 1B IND for TCB-008 in Acute Myeloid Leukemia.
    • Alithya Group Inc. (NASDAQ:ALYA) shares gained 9.6% to $1.26 in pre-market trading. The company recently posted an increase in third-quarter sales.
    • Starbox Group Holdings Ltd. (NASDAQ:STBX) shares climbed 9% to $0.3290 in pre-market trading after dipping 15% on Monday.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) gained 7.7% to $1.68 in pre-market trading after gaining around 24% on Monday. Professional Diversity recently posted a narrower quarterly loss.

    Losers

    • Tharimmune, Inc. (NASDAQ:THAR) dipped 67.4% to $1.14 in pre-market trading. Tharimmune priced its $10 million public offering 10 million common shares at $1 per share.
    • SenesTech, Inc. (NASDAQ:SNES) shares fell 35.1% to $1.20 in pre-market trading after the company reported pricing of $5.0 million public offering.
    • CohBar, Inc. (NASDAQ:CWBR) fell 33.4% to $0.5997 in pre-market.
    • Next.e.GO N.V. (NASDAQ:EGOX) shares fell 19.5% to $0.4426 in pre-market trading after gaining around 8% on Monday.
    • Nexalin Technology, Inc. (NASDAQ:NXL) shares fell 19.3% to $0.2712 in pre-market trading.
    • Mobiquity Technologies, Inc. (NASDAQ:MOBQ) fell 15.3% to $0.3912 in pre-market trading.
    • argenx SE (NASDAQ:ARGX) fell 14.4% to $423.80 in pre-market trading after the company reported topline results from ADVANCE-SC study of VYVGART hytrulo in primary immune thrombocytopenia.
    • Yield10 Bioscience, Inc. (NASDAQ:YTEN) shares fell 13.6% to $0.21 in pre-market trading. Maxim Group recently downgraded Yield10 Bioscience from Buy to Hold.
    • GlucoTrack, Inc. (NASDAQ:GCTK) shares fell 8.3% to $0.1898 in pre-market trading after gaining 7% on Monday.
    • Asset Entities Inc. (NASDAQ:ASST) fell 7.4% to $0.6125 in pre-market trading. Asset Entities shares jumped over 88% on Monday after the company announced a stock repurchase program.

     

    Now Read This: Intuit, NetApp And 3 Stocks To Watch Heading Into Tuesday

    Get the next $ALYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALYA
    $ARGX
    $ASST
    $CWBR

    CompanyDatePrice TargetRatingAnalyst
    argenx SE
    $ARGX
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    argenx SE
    $ARGX
    11/24/2025Outperform → Peer Perform
    Wolfe Research
    argenx SE
    $ARGX
    9/15/2025$918.00Buy
    Truist
    argenx SE
    $ARGX
    9/11/2025Buy → Hold
    Deutsche Bank
    argenx SE
    $ARGX
    8/25/2025$850.00Outperform
    RBC Capital Mkts
    argenx SE
    $ARGX
    7/8/2025Hold → Buy
    Deutsche Bank
    argenx SE
    $ARGX
    7/3/2025$700.00Overweight
    Morgan Stanley
    argenx SE
    $ARGX
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

    Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronida

    2/26/26 12:30:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mobiquity Technologies and Context Networks Expand Casino Media Network Reach and Scale Through Nationwide ATM Integration

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (OTCQB:MOBQ) and Context Networks today announced a strategic expansion of their casino-focused media ecosystem through the integration of digital advertising capabilities across a nationwide ATM infrastructure. This initiative transforms high-traffic ATM locations into programmatic digital media assets, significantly extending the networks scale while enhancing advertisers' ability to execute targeted campaigns within key Designated Market Areas (DMAs). The ATM footprint spans more than 120,000 machines operated by thousands of independent operators nationwide, creating substantial incremental digital out-of-home (

    2/25/26 8:30:00 AM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    $ALYA
    $ARGX
    $ASST
    $CWBR
    SEC Filings

    View All

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    2/26/26 8:37:08 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    2/26/26 6:20:37 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nexalin Technology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Nexalin Technology, Inc. (0001527352) (Filer)

    2/25/26 2:29:45 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Financial Officer Pham Benjamin bought $115,095 worth of shares (14,114 units at $8.15) (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/19/26 8:00:23 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Chief Legal Officer Beirne Brian Logan bought $100,387 worth of shares (11,500 units at $8.73), increasing direct ownership by 310% to 15,204 units (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/17/26 8:02:53 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Financial Officer Pham Benjamin bought $115,095 worth of shares (14,114 units at $8.15) (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/19/26 8:00:23 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Chief Legal Officer Beirne Brian Logan bought $100,387 worth of shares (11,500 units at $8.73), increasing direct ownership by 310% to 15,204 units (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/17/26 8:02:53 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    argenx downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded argenx from Outperform to Neutral and set a new price target of $858.00

    12/18/25 8:54:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Wolfe Research

    Wolfe Research downgraded argenx from Outperform to Peer Perform

    11/24/25 8:14:37 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on argenx with a new price target

    Truist resumed coverage of argenx with a rating of Buy and set a new price target of $918.00

    9/15/25 7:47:59 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALYA
    $ARGX
    $ASST
    $CWBR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    11/27/23 5:34:21 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    11/27/23 5:34:04 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Financials

    Live finance-specific insights

    View All

    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f

    2/26/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

    February 19, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium           32 800 50

    2/19/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RF-Based VRU Safety Platforms Positioned for Institutional-Scale Growth

    Next-Generation RF Sensors Power the Future of Vulnerable Road User Protection NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Market News Updates News Commentary - The Vulnerable Road User (VRU) RF sensing platform market focuses on technology that helps vehicles and smart roads detect pedestrians, cyclists, and other people most at risk in traffic. These platforms use radio-frequency (RF) sensing, such as radar and mmWave, to "see" movement around vehicles in real time. Unlike cameras alone, RF sensing works well at night, in bad weather, and in crowded urban areas, making it a reliable safety solution as cities and vehicles become more automated.  Active Companies to keep a close eye on include: 

    2/6/26 9:15:00 AM ET
    $APTV
    $MGA
    $ON
    Auto Parts:O.E.M.
    Consumer Discretionary
    Semiconductors
    Technology

    $ALYA
    $ARGX
    $ASST
    $CWBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/20/24 7:44:24 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/14/24 7:18:49 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary